D. Bulchandani

Association of Exenatide With Liver Enzymes in Patients With Type 2 Diabetes

M. S. Hamburg, D. Bulchandani, J. Nachnani, 2009 .

Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin

D. Bulchandani, J. Nachnani, L. Alba, 2010, Annals of Hematology.

Incidence of Diabetes Following Pancreatic Necrosectomy

D. Bulchandani, J. Nachnani, L. Weide, 2008 .

Patient and physician predictors of inappropriate acid-suppressive therapy (AST) use in hospitalized patients.

D. Bulchandani, J. Nachnani, J. Moormeier, 2009, Journal of hospital medicine.

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

D. Bulchandani, J. Nachnani, L. Weide, 2009, Diabetologia.

Treatment with Ω-3 fatty acids but not exendin-4 improves hepatic steatosis

D. Bulchandani, J. Nachnani, L. Alba, 2010, European journal of gastroenterology & hepatology.

Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes.

M. S. Hamburg, D. Bulchandani, Tara Konrady, 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Beyond MRSA: the growing menace of hVISA and VISA.

D. Bulchandani, J. Nachnani, J. Brewer, 2008, Southern medical journal.

Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model.

D. Bulchandani, J. Nachnani, L. Alba, 2012, European journal of pharmacology.

Megestrol acetate-associated adrenal insufficiency.

D. Bulchandani, J. Nachnani, A. Amin, 2008, The American journal of geriatric pharmacotherapy.

Why do omega-3 fatty acids lower serum triglycerides?

W. Harris, D. Bulchandani, Deepti Bulchandani, 2006, Current opinion in lipidology.